Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial

We prospectively evaluated the safety and efficacy of a clofarabine, intravenous busulfan and antithymocyte globulin-based reduced-toxicity conditioning (CloB2A2) regimen before allogeneic stem cell transplantation. Thirty high-risk patients (median age: 59 years; acute myeloid leukemia n=11, acute...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Chevallier, Patrice, Labopin, Myriam, Socié, Gérard, Tabrizi, Reza, Furst, Sabine, Lioure, Bruno, Guillaume, Thierry, Delaunay, Jacques, de La Tour, Régis Peffault, Vigouroux, Stéphane, El-Cheikh, Jean, Blaise, Didier, Michallet, Mauricette, Bilger, Karin, Milpied, Noel, Moreau, Philippe, Mohty, Mohamad
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2014
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562538/
https://ncbi.nlm.nih.gov/pubmed/24951467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.108563
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires